Syndax pharmaceuticals inc (SNDX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue:
Total revenues

379

380

379

379

379

380

379

379

379

1,193

305

305

305

-

-

-

-

-

-

-

-

Total revenues

379

380

379

379

379

380

379

379

379

1,193

305

305

305

-

-

-

-

-

-

-

-

License fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

305

305

305

-

305

17

-

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

305

305

305

-

305

17

-

Operating expenses:
Research and development

9,562

9,502

9,923

12,290

11,279

15,821

14,095

14,851

15,339

16,599

12,188

9,862

9,552

8,474

12,274

6,131

4,786

2,587

2,968

2,271

1,723

General and administrative

5,917

5,083

3,605

3,463

3,911

3,892

4,125

4,479

4,791

4,083

3,563

4,285

3,930

2,972

3,269

2,808

4,272

2,397

3,195

3,288

2,711

Total operating expenses

15,479

14,585

13,528

15,753

15,190

19,713

18,220

19,330

20,130

20,682

15,751

14,147

13,482

11,446

15,543

8,939

9,058

4,984

6,163

5,559

4,434

Loss from operations

-15,100

-14,205

-13,149

-15,374

-14,811

-19,333

-17,841

-18,951

-19,751

-19,489

-15,446

-13,842

-13,177

-11,141

-15,238

-8,634

-8,753

-4,679

-5,858

-5,542

-4,434

Other (expense) income:
Interest expense

449

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

333

-

-

-

452

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

268

268

276

144

-524

-229

-322

-339

Change in fair value of common stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,703

70

1,607

346

132

Other (expense) income

-20

-17

-76

-43

57

-

-

-

-

-

-

-

-

58

1

0

-18

10

-37

-4

-6

Total other (expense) income

-136

205

320

458

509

496

503

563

353

385

358

203

206

326

269

276

-1,577

-584

-1,873

-672

-477

Net loss

-15,236

-14,000

-12,829

-14,916

-14,302

-18,837

-17,338

-18,388

-19,398

-19,104

-15,088

-13,639

-12,971

-10,815

-14,969

-8,358

-10,330

-5,263

-7,731

-6,214

-4,911

Other comprehensive income (loss):
Unrealized gain on marketable securities

48

-

-33

50

33

-

-

-

-

-

-

-

-

-

-92

-36

200

-

-

-11

3

Comprehensive loss

-15,188

-

-12,862

-14,866

-14,269

-

-

-

-

-

-

-

-

-

-15,061

-8,394

-10,130

-

-

-6,225

-4,908

Net loss attributable to common stockholders

-19,142

-14,000

-12,829

-14,916

-14,302

-

-

-

-

-

-

-

-

-10,815

-14,969

-8,358

-12,928

-8,779

-56,656

-26,338

-12,072

Net loss per share attributable to common stockholders—basic and diluted

-0.56

-0.44

-0.41

-0.47

-0.53

0.70

0.68

0.74

0.79

-0.80

-0.84

-0.47

-2.85

0.94

-0.84

-0.47

-2.85

-81.60

-790.85

-440.52

-206.30

Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—basic and diluted

34,328

31,640

31,630

31,605

27,023

26,804

25,471

24,705

24,478

23,943

22,239

19,497

18,231

18,268

17,899

17,769

4,541

83

71

59

58